Date: 2018-02-05
Type of information: Nomination
Compound: member of the scientific advisory board
Company: Oryzon Genomics (Spain)
Therapeutic area: Cancer - Oncology - Neurodegenerative diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On February 5, 2018, Oryzon Genomics has announced another key addition to its Scientific Advisory Board (SAB) to reinforce its development capabilities for its epigenetic drug ORY-1001 in leukemia and solid tumors with the appointment of Dr. Lori A. Kunkel. Dr. Kunkel has more than two decades of experience in oncology and immunology drug development and commercialization. Kunkel began her career in industry as a clinical scientist at Genentech working on the development of Rituxan®. Dr. Kunkel presently serves on the Board of Directors of Loxo Oncology, Curis, Tocagen and Maverick Therapeutics. She was previously the acting Chief Medical Officer at Loxo and she served as Chief Medical Officer at Pharmacyclics (acquired by AbbVie) and Proteolix (acquired by Onyx Pharmaceuticals), contributed to the approvals of cancer therapeutics Imbruvica® and Kyprolis®,
respectively. She has advised multiple clients including Chiron (acquired by Novartis), Genentech/Roche,
Salmedics (acquired by Celgene), Stemcentrx (acquired by Abbvie), Amphivena Therapeutics, Atreca and Verastem.
Dr. Kunkel served as a faculty member in the Division of Hematology/Oncology at University of California, Los
Angeles. Dr. Kunkel obtained a medical degree from University of Southern California and a bachelor's
degree in biology from University of California, San Diego. She is board certified in internal medicine and held
board certifications in hematology and oncology.
Financial terms:
Latest news:
Is general: Yes
